

Please try another search
Investing.com - Kiniksa Pharma (NASDAQ: KNSA) reported fourth quarter EPS of $-0.18, $0.03 better than the analyst estimate of $-0.20. Revenue for the quarter came in at $39.9M versus the consensus...
Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) reported Q2 EPS of ($0.29), $0.14 better than the analyst estimate of ($0.43). Revenue for the quarter came in at $26.97 million versus the consensus...
By Julie Steenhuysen CHICAGO (Reuters) - A U.S. man with terminal heart disease was implanted with a genetically modified pig heart in a first-of-its-kind surgery, and three days later the patient is...
By Sam Boughedda Investing.com — Shares of Kiniksa Pharmaceuticals Ltd (NASDAQ:KNSA) are down 7% Tuesday after falling over 16% premarket on the back of news that its phase 3 trial of mavrilimumab...
By Daniel Shvartsman Investing.com -- Stocks in focus in pre-market trade on Tuesday, December 28th. Prices as of 8:30am ET, please refresh to see updated pricing. Tesla (NASDAQ:TSLA) traded up 1.8%...
Evercore ISI analyst Liisa Bayko maintained a Buy rating on Kiniksa Pharmaceuticals (NASDAQ:KNSA) Ltd on Wednesday, setting a price target of $25, which is approximately 66.22% above the present share...
On the 31st of March, Arrowpoint Asset Management bought 2.3 million 2U, Inc. (NASDAQ:TWOU) shares for $88 million at an average price of $38.23 per share. Shares of 2U, Inc. are up 0.37% since the...
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review